Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Paul Van Daele et al.|NEJM Evidence|2023Cited by 74
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)Jason Gotlib, Srđan Verstovšek, Jean‐Jacques Kiladjian et al.|Blood|2021Cited by 51
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Andreas Reiter, Juliana Schwaab et al.|The Journal of Allergy and Clinical Immunology In Practice|2022Cited by 20
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated PatientsSrđan Verstovšek, Jean‐Jacques Kiladjian, Jason Gotlib et al.|Blood|2022Cited by 14
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working GroupWilliam Shomali, Jason Gotlib, Philomena Colucci et al.|Leukemia|2023Cited by 14